A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

BACKGROUND: Inhibitors of poly(ADP‐ribose) polymerase (PARP) proteins potentiate antitumor activity of platinum chemotherapy. This study sought to determine the safety and tolerability of PARP inhibitor talazoparib with carboplatin and paclitaxel. METHODS: We conducted a phase I study of talazoparib...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal, Ticiana A., Sharifi, Marina N., Chan, Nancy, Wesolowski, Robert, Turk, Anita A., Bruce, Justine Y., O'Regan, Ruth M., Eickhoff, Jens, Barroilhet, Lisa M., Malhotra, Jyoti, Mehnert, Janice, Girda, Eugenia, Wiley, Elizabeth, Schmitz, Natalie, Andrews, Shannon, Liu, Glenn, Wisinski, Kari B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636507/
https://www.ncbi.nlm.nih.gov/pubmed/35396812
http://dx.doi.org/10.1002/cam4.4724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636507/
https://www.ncbi.nlm.nih.gov/pubmed/35396812
http://dx.doi.org/10.1002/cam4.4724

Ejemplares similares